Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Graeser, Monika; Schrading, Simone; Gluz, Oleg; Strobel, Kevin; Herzog, Christopher; Umutlu, Lale; Frydrychowicz, Alex; Rjosk-Dendorfer, Dorothea; Würstlein, Rachel; Culemann, Ralph; Eulenburg, Christine; Adams, Jascha; Nitzsche, Henrik; Prange, Anna; Kümmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Potenberg, Jochem; von Schumann, Raquel; Aktas, Bahriye; Kolberg-Liedtke, Cornelia; Harbeck, Nadia; Kuhl, Christiane K.; Nitz, Ulrike

doi:10.1186/s13058-021-01413-y

Table 3 Prediction of pCR and residual tumor size in the MRI group and in the US group

From: Magnetic resonance imaging and ultrasound for prediction of residual tumor size in early breast cancer within the ADAPT subtrials

Group		pCR, N	CR, N	TN, N	FP, N	TP, N	FN, N	Specificity (CL)	Sensitivity (CL)	NPV (CL)	PPV (CL)
Overall	MRI (N = 244)	89	84	61	28	132	23	0.69 (0.58–0.78)	0.85 (0.79–0.90)	0.73 (0.62–0.82)	0.83 (0.76–0.88)
Overall	US (N = 578)	218	149	101	117	312	48	0.46 (0.40–0.53)	0.87 (0.83–0.90)	0.68 (0.60–0.75)	0.73 (0.68–0.77)
HR+/HER2+	MRI (N = 103)	34	25	19	15	63	6	0.56 (0.38–0.73)	0.91 (0.82–0.97)	0.76 (0.55–0.91)	0.81 (0.70–0.89)
HR+/HER2+	US (N = 252)	83	62	39	44	146	23	0.47 (0.36–0.58)	0.86 (0.80–0.91)	0.63 (0.50–0.75)	0.77 (0.70–0.83)
HR−/HER2−	MRI (N = 91)	31	38	22	9	44	15	0.71 (0.52–0.86)	0.73 (0.60–0.84)	0.58 (0.41–0.74)	0.83 (0.70–0.92)
HR−/HER2−	US (N = 242)	93	65	48	45	132	17	0.52 (0.41–0.62)	0.89 (0.82–0.93)	0.74 (0.62–0.84)	0.75 (0.68–0.81)
HR−/HER2+	MRI (N = 50)	24	21	20	4	25	1	0.83 (0.63–0.95)	0.96 (0.80–1)	0.95 (0.76–1)	0.86 (0.68–0.96)
HR−/HER2+	US (N = 84)	42	22	14	28	34	8	0.33 (0.20–0.50)	0.81 (0.66–0.91)	0.64 (0.41–0.83)	0.55 (0.42–0.68)
Group		≤10 mm at histology, N	≤10 mm at imaging, N	TN, N	FP, N	TP, N	FN, N	Specificity (CL)	Sensitivity (CL)	NPV (CL)	PPV (CL)
Overall	MRI (N = 224)	151	100	92	59	65	8	0.61 (0.53–0.69)	0.89 (0.80–0.95)	0.92 (0.85–0.96)	0.52 (0.43–0.62)
Overall	US (N = 560)	353	306	253	100	154	53	0.72 (0.67–0.76)	0.74 (0.68–0.80)	0.83 (0.78–0.87)	0.61 (0.54–0.67)
HR+/HER2+	MRI (N = 101)	61	30	27	34	37	3	0.44 (0.32–0.58)	0.93 (0.80–0.98)	0.90 (0.74–0.98)	0.52 (0.40–0.64)
HR+/HER2+	US (N = 246)	142	138	106	36	72	32	0.75 (0.67–0.82)	0.69 (0.59–0.78)	0.77 (0.69–0.84)	0.67 (0.57–0.75)
HR−/HER2−	MRI (N = 81)	55	45	40	15	21	5	0.73 (0.59–0.84)	0.81 (0.61–0.93)	0.89 (0.76–0.96)	0.58 (0.41–0.74)
HR−/HER2−	US (N = 237)	156	124	107	49	64	17	0.69 (0.61–0.76)	0.79 (0.69–0.87)	0.86 (0.79–0.92)	0.57 (0.47–0.66)
HR−/HER2+	MRI (N = 42)	35	25	25	10	7	0	0.71 (0.54–0.85)	1 (0.59–1)	1 (0.86–1)	0.41 (0.18–0.67)
HR−/HER2+	US (N = 77)	55	44	40	15	18	4	0.73 (0.59–0.84)	0.82 (0.60–0.95)	0.91 (0.78–0.98)	0.55 (0.36–0.72)

TP, true-positive examination; FP, false-positive examination; TN, true-negative examination and FN; false-negative examination. For pCR, TN was defined as CR at imaging and pCR, FP as no CR at imaging and pCR, TP as no CR at imaging and no pCR, and FN as CR at imaging and no pCR. For residual tumor at histology, TN was defined as tumor size of ≤10 mm by imaging and equivalent tumor size at histology, FP was defined as tumor size of > 10 mm by imaging and tumor size of ≤10 mm at histology; TP was defined as tumor size of > 10 mm by imaging and equivalent tumor size at histology, and FN was defined as tumor size of ≤10 mm by imaging and tumor size of > 10 mm at histology. PPV, positive predictive value, defined as P(P = 1|I = 1); NPV, negative predictive value, defined as P(P = 0|I = 0); SENS, sensitivity, defined as P(I = 1|P = 1); SPEC, specificity, defined as P(I = 0|P = 0 where P(A|B) denotes the conditional probability of event A given that event B has occurred. P = 1 denotes a residual invasive tumor size of > 10 mm at histology, and I = 1 denotes tumor size of > 10 mm at imaging; CL, exact 95% confidence limits (Clopper-Pearson)

Back to article page

ISSN: 1465-542X

Contact us

Submission enquiries: journalsubmissions@springernature.com

Breast Cancer Research

Contact us